Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Sirona Biochem Corp. (SRBCF)
Vancouver, BC, CA
Sirona Biochem Corp. operates as a biotechnology company dedicated to uncovering and commercializing active ingredients for both cosmetic and pharmaceutical uses, with a commercial presence in Canada and France. Key initiatives include the development of a cosmetic skin brightener and a pharmaceutical solution for diabetes. Beyond these, the company is engaged in several other projects, such as building a library of anti-aging and cell-protective compounds, creating a novel anti-wrinkle agent, and pursuing an antiviral research program. A notable collaboration exists with the International Centre for Genetic Engineering and Biotechnology (ICGEB) for the joint development of an antiviral compound library. Established in 2006, the business, originally named High Rider Capital Inc., rebranded as Sirona Biochem Corp. in May 2009 and maintains its headquarters in Vancouver, Canada.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | +18.60% | -94.38% | -97.99% | -96.29% | -91.50% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
-
Revenue growth Biotechnology: +1.6%-94.8% Q3'24: -62.7% (vs Q3'23)
-
EPS growth Biotechnology: +29.7%+31.8% ★ Q3'24: -61.9% (vs Q3'23)
-
FCF margin FCF growth · Biotechnology: +16.2%-5,694.3% Q3'24: -21,729.8% (vs Q3'23)
-
EBIT margin Biotechnology: +0.0%-6,735.4% Q3'24: -26,136.3% (vs Q3'23)
-
ROIC Biotechnology: -16.1%— Q3'24: +1,488.9% (vs Q3'23)
-
Share dilution Biotechnology: -3.4%+4.6% Q3'24: +2.6% (vs Q3'23)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.94× Q3'24: -1.25× (vs Q3'23)
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Géraldine Deliencourt-Godefroy | Chief Scientific Officer & Director | 154.1K | — |
| Howard J. Verrico | Founder, Chairman of the Board, Chief Executive Officer & Secretary | 21.7K | — |
| Christopher D. Hopton | Chief Financial Officer & Director | 17.8K | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for SRBCF
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
